Equity Research Medical Devices

Should You Buy Vycor Medical, Inc. Stock in 2026?

By CirclFi Research Team · · Updated · 3/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Vycor Medical, Inc. (VYCO) carries a solid Quality of Company rating of 6.0/10. Trading at $0.07, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.

The short answer: 1 of 3 CirclFi valuation models project upside for Vycor Medical, Inc. (VYCO) at $0.07 — the model consensus leans bearish, with a Quality Score of 6.0/10 and Value-Trap risk of 26/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 2 of 3 models suggest overvaluation — majority bearish
  • Quality Score: 6.0/10 — Moderate — mixed signals
  • Value Trap Risk: 26/100 — Low — manageable risk
  • Fair Value Range: $0.04 – $0.07 (76% spread)

Bullish Models

1 / 3

Bearish Models

2 / 3

Quality Score

6.0 /10

Moderate — mixed signals

Value Trap Risk

26 /100
Low

Low — manageable risk

Model Consensus

3 /13
Active Models

Avg. confidence: 36%

What Is the Investment Case for Vycor Medical, Inc. (VYCO) in 2026?

What Is the Bull Case vs the Bear Case for Vycor Medical, Inc. (VYCO)?

Bull case versus bear case for Vycor Medical, Inc. (VYCO) at $0.07, derived from 3 active CirclFi valuation models on 2026-10-07.
Bull case — $0.07 target (+2.3%) Bear case — $0.04 target (-41.9%)
Industry tailwind: licensing and M&A optionality could provide meaningful support for Vycor Medical, Inc.'s revenue and margin trajectory in the Medical Devices space. According to the CirclFi Deep Alpha Valuation Engine, the Sentiment SOTP model sees the stock as overvalued with a fair value of $0.04 (-41.9%), suggesting that the market price embeds overly optimistic growth assumptions.
Industry headwind: generic/biosimilar competition represents a meaningful risk for Vycor Medical, Inc. and its Medical Devices peers.

How Does VYCO Compare to Its Medical Devices Peers?

AIDX 20/20 Biolabs, Inc.
6.0
SSII SS Innovations Inter
6.0
RPID Rapid Micro Biosyste
6.1
BTCY Biotricity, Inc.
6.0
NMTC NeuroOne Medical Tec
6.1
LAB Standard BioTools In
5.9
ALUR Allurion Technologie
4.8
ABT Abbott Laboratories
8.8

Valuation data pages: AIDX · SSII · RPID · BTCY · NMTC · LAB · ALUR · ABT · MXCT · IRMD · PODD

See full Medical Devices rankings →

Which Other Stocks Score Like VYCO on Quality?

Closest companies to VYCO’s Quality of Company score of 6.0/10, across all industries.

Why Do CirclFi’s 3 Models Disagree on VYCO?

Spread

76%

Fair Value Range

$0.04 – $0.07

A 76% spread represents moderate disagreement. The models agree on direction but differ on magnitude.

Most Bullish

First Chicago

$0.07 (+2.3%)

Most Bearish

Sentiment SOTP

$0.04 (-41.9%)

What Are the Biggest Risks of Buying VYCO Stock?

Bearish Consensus

2/3 models suggest overvaluation.

Macro/Sector Risk

Medical Devices headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View VYCO Data Page →

So Is Vycor Medical, Inc. (VYCO) Worth Buying in 2026?

Caution dominates our read on Vycor Medical, Inc. at $0.07. 2 of 3 models see limited upside or outright downside, with the median fair value at $0.06 (-15.0%). Quality at 6.0/10 provides some fundamental cushion. Current holders should re-evaluate their thesis; new buyers should demand a wider margin of safety.

These are quantitative model outputs, not investment recommendations. Vycor Medical, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About VYCO Stock?

Should I buy VYCO stock right now?

Based on CirclFi's multi-model analysis, 1 of 3 models see upside for VYCO at $0.07. The models are divided, which means the investment case depends heavily on your assumptions about Vycor Medical, Inc.'s future. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Vycor Medical, Inc.?

Key risks include: limited model coverage (3/13 active), reducing analytical confidence; general market and sector-specific risks affecting Medical Devices companies. Always diversify and consult a financial advisor.

How does VYCO compare to its competitors?

Among Medical Devices peers, VYCO holds a Quality Score of 6.0/10. Comparable companies include AIDX (QOC 6.0), SSII (QOC 6.0), RPID (QOC 6.1). The relative ranking helps investors identify whether VYCO offers better fundamental quality than alternatives in the same sector.

Is VYCO a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. VYCO's Quality Score of 6.0/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.

What price should I buy VYCO at?

CirclFi does not provide target buy prices or price alerts. However, our 3 active models produce fair value estimates ranging from $0.04 to $0.07. At $0.07, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for VYCO.

View VYCO Data Page Full Terminal — $60/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →